Veeva's Exiting President Sold $2.8 Million in Stock: What Investors Need to Know
Key Points
The sale of 10,000 shares on Aug. 27, 2026, generated $2.8 million in gross proceeds at a weighted-average execution price.
The transaction size equaled 51% of the direct equity stake held before the filing.
The disposition followed the exercise of 10,000 stock options at $154.00 per share and was conducted under a Rule 10b5-1 trading plan.
Following the transaction, the executive retains a direct holding of 19,449 shares and 25,000 derivative securities.
Thomas D. Schwenger, Pres. & Chief Customer Officer at Veeva Systems Inc. (NYSE:VEEV), executed a sale of 10,000 shares of Class A Common Stock on Aug. 27, 2026, for a total value of $2.8 million according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $2.8 million |
| Shares sold (directly held) | 10,000 |
| Post-transaction shares (directly held) | 19,449 |
| Post-transaction value | $5.49 million |
Transaction value based on SEC Form 4 weighted average sale price ($281.33); post-transaction value based on Aug. 27, 2026, market close ($282.13).
Key questions
- What was the structural mechanism for this transaction?
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Thomas D. Schwenger, which establishes pre-arranged trade parameters to manage equity exposure and personal liquidity. - How did the transaction price compare to recent market levels?
The shares were sold at a weighted average price of $281.33, while the stock was priced at $276.69 as of the Aug. 28, 2026, market close. - What is the status of the insider's remaining equity position?
In addition to 19,449 directly held shares of common stock, the executive maintains 25,000 derivative securities, ensuring continued alignment with the cloud-based software solutions provider. - What was the total shareholder return context for this trade?
At the time of the transaction on Aug. 27, 2026, the company's one-year total return was -4%.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-02) | $280.72 |
| Market Capitalization | $44.9 billion |
| Revenue (TTM) | $3.5 billion |
| Net Income (TTM) | $1.0 billion |
Company Snapshot
- Veeva Systems provides cloud-based software solutions exclusively serving the global life sciences industry, with primary revenue streams derived from the Veeva Commercial Cloud and Veeva Vault product suites that deliver integrated software, data, and analytics capabilities.
- The company operates a subscription-based SaaS business model, generating recurring revenue through cloud platform licensing, professional services, and data analytics offerings that optimize commercial operations and regulatory compliance for pharmaceutical, biotechnology, and medical device manufacturers.
- Veeva's customer base comprises leading global life sciences organizations across North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America, serving enterprises seeking to streamline commercial execution, clinical development, and regulatory workflows.
Veeva Systems is a specialized enterprise software provider with a $44.9 billion market capitalization and $3.5 billion in TTM revenue, demonstrating substantial scale within the life sciences vertical. The company maintains a competitive advantage through deep domain expertise, comprehensive product integration, and an extensive global customer base spanning the entire life sciences value chain. With net income of $1.0 billion TTM, Veeva exhibits strong profitability and cash generation characteristics typical of mature SaaS platforms serving mission-critical enterprise functions.
What this transaction means for investors
President Schwenger's $2.8 million sale may look alarming, but it shouldn't be something investors plan trades around. First, the President is departing on Oct. 2, 2026, so we should not place too much value on what they do with their shares. Furthermore, the sale was preplanned, so it wasn't a bet on the stock's future performance but rather a routine liquidity-raising for a C-suite executive.
As for Veeva Systems stock itself, the company is rebounding dramatically following the "SaaS-pocalypse" over the past year, during which many investors feared AI might displace most software stocks. Veeva smashed earnings twice and proved that its transition away from Salesforce's (NYSE:CRM) CRM to its own Veeva Vault CRM is going well, causing its stock to rocket 55% higher over the last six months.
While Veeva might not have a ton of optionality outside of the life sciences niche it operates in, management estimates it has a 16% market share in the $20 billion life sciences industry, so there is plenty of room to grow. This is especially true as Veeva develops an expanding portfolio of younger product lines. This is still a promising growth stock, with sales rising in the double digits annually, but trading at 40 times FCF (including stock-based compensation), I'm not desperate to add to my already hefty position after the stock's recent run.
Josh Kohn-Lindquist has positions in Veeva Systems. The Motley Fool has positions in and recommends Salesforce and Veeva Systems. The Motley Fool has a disclosure policy.